The Arthritis Foundation recently convened its Fourth industry forum in Washington, D.C. bringing together 50 industry stakeholders that represented 20 organizations. Attendees represented pharmaceutical, biotech, academic and governmental institutions with representatives from the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and the NIH/NIAMS.
Once again, the AIF provided a rare opportunity for unfiltered public health discussions. This year’s topics included health care reform implementation, FDA policy and how arthritis adversely and disproportionately impacts disparate and diverse populations.
These public health stakeholders had the opportunity to share ideas and mine collaborative opportunities to address vital issues in the prevention, control and cure of arthritis.
Photos courtesy of Max Taylor photography